Our services: The SAT advantage

The powerful capabilities of SPOT-AI are deployed through the Sygnomics Analytics Test (SAT), which analyzes RNA sequencing data (i.e., “molecular tumor profile”) from CAP/CLIA certified tests to:

  • Delineate active transcriptional programs driving disease progression
  • Predict treatment response in individual patients
  • Prioritize therapies based on mechanistic understanding, not just statistical correlation
  • Provide interpretable, evidence-based rationales for treatment recommendations

SPOT-AI uses explainable AI, showing exactly how and why specific treatments are recommended for each patient.

Example SAT report

Evidence of efficacy

Our systems approach significantly outperforms current clinical tests in risk stratification. In independent studies, cancer cells from both glioblastoma and multiple myeloma patients were significantly more sensitive to drugs recommended by our technology. And studies showed that glioblastoma patients stayed on their Sygnomics-recommended treatments up to five times longer than patients who received treatments deemed ineffective by our system.

See the evidence for multiple myeloma > See the evidence for glioblastoma >

It’s time to improve the statistics

SPOT-AI transforms cancer care from a population-level “drug-centric” approach to an N-1 “patient-centric” approach. While most cancer drugs fail in clinical trials and approved therapies work for fewer than 25% of patients, SPOT-AI reveals the true drivers of an individual’s cancer, helping oncologists make more effective, personalized treatment decisions and improving the patient’s outcomes.

Investigative Portals

Explore the portals that assisted in our research.

Multiple Myeloma Network Portal

This interactive portal facilitates a thorough investigation of the causal and mechanistic transcriptional regulatory network model for multiple myeloma.

Glioblastoma Network Portal

The GBM network portal was developed to provide easy access to the gbmSYGNAL network by allowing searching of somatically mutated genes, regulators, or genes in biclusters.

Transcription Factor Target Gene Database

This database targets gene interactions that were built to facilitate the construction of gene regulatory networks.

Excited about Sygnomics’ technology? Get involved.

Our work promises to change the future of oncology therapeutics—and deliver better tomorrows for millions of cancer patients. You could play a part through investing, collaborating with us, or working on our talented team of scientists, engineers and business experts. Let’s talk about how you can get involved.